FDA's import-screening program sidelined by IT issues

IT problems are being cited in the FDA delay of PREDICT, the Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting initiative. The program is intended to help customs officers prevent adulterated and counterfeit drugs from entering the U.S.

Commissioner Margaret Hamburg unveiled PREDICT in early February. Implementation was expected this spring, reports SecuringPharma. The system uses barcode readers to access a central database in its objective of prioritizing imports for inspection using risk-based techniques, along the lines of those advocated by the regulator for use in drug manufacturing.

The project involves an initial roll-out in New York, following testing in Los Angeles.

- see the story

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.